GeneDx Holdings Corp. (NASDAQ: WGS) shares plunged nearly 50% after the company posted a significant first-quarter loss and cut its 2026 revenue forecast, prompting a securities fraud investigation.
"The company also took a $31.3 million write-down related to the goodwill and intangible assets of its Fabric Genomics reporting unit," The Law Offices of Frank R. Cruz said in a statement announcing its investigation.
GeneDx reported a Q1 loss of $0.28 per share on revenue of $102.3 million, missing analyst estimates. The company lowered its full-year revenue guidance to a range of $475 million to $490 million, down from a previous forecast of $540 million to $555 million, citing lower reimbursement rates and weaker performance in non-core business lines.
The dramatic sell-off erased nearly half of the company's market value, with the stock hitting its lowest point since its public debut. The announced investigations by shareholder rights law firms, including Block & Leviton, could lead to a class-action lawsuit, adding legal and financial pressure on the company.
The genetics testing company revealed a $57.5 million loss from operations in its first-quarter 2026 financial results. The poor performance was attributed to a "lower-than-expected blended average reimbursement rate for exome and genome" and "softer-than-expected performance from [its] non-core business lines," including Fabric Genomics. This led to a $31.3 million write-down related to the goodwill and intangible assets of the Fabric Genomics unit.
Following the news, which was released after market hours on May 4, 2026, GeneDx's stock price fell as much as 50% during intraday trading on May 5, 2026.
The stock's collapse and pending legal battles create significant uncertainty for GeneDx. Investors will be closely watching for the outcome of the securities fraud investigations and any management response to the operational challenges.
This article is for informational purposes only and does not constitute investment advice.
